» Authors » Karthik Tiruthani

Karthik Tiruthani

Explore the profile of Karthik Tiruthani including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 613
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Shen L, Schaefer A, Tiruthani K, Wolf W, Lai S
Bioeng Transl Med . 2024 Nov; 9(5):e10651. PMID: 39553435
An ideal tumor-specific immunomodulatory therapy should both preferentially target the tumor, while simultaneously reduce the immunosuppressive environment within the tumor. This guiding principle led us to explore engineering Siglec-15 (S15)...
2.
Tiruthani K, Cruz-Teran C, Chan J, Ma A, McSweeney M, Wolf W, et al.
Bioeng Transl Med . 2024 Jul; 9(4):e10650. PMID: 39036085
Soluble angiotensin-converting enzyme 2 (ACE2) can act as a decoy molecule that neutralizes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by blocking spike (S) proteins on virions from binding ACE2...
3.
McSweeney M, Stewart I, Richardson Z, Kang H, Park Y, Kim C, et al.
Bioeng Transl Med . 2022 Oct; :e10391. PMID: 36248234
The respiratory tract represents the key target for antiviral delivery in early interventions to prevent severe COVID-19. While neutralizing monoclonal antibodies (mAb) possess considerable efficacy, their current reliance on parenteral...
4.
Shen L, Li J, Liu Q, Das M, Song W, Zhang X, et al.
J Control Release . 2022 Feb; 343:303-313. PMID: 35104570
Interactions between different cell types in the tumor microenvironment (TME) affect tumor growth. Tumor-associated fibroblasts produce C-X-C motif chemokine ligand 13 (CXCL13) which recruits B cells to the TME. B-cells...
5.
Wang Y, Tiruthani K, Li S, Hu M, Zhong G, Tang Y, et al.
Adv Mater . 2021 May; 33(23):e2007603. PMID: 33945178
Liver malignancies are among the tumor types that are resistant to immune checkpoint inhibition therapy. Tumor-associated macrophages (TAMs) are highly enriched and play a major role in inducing immunosuppression in...
6.
Liu Y, Tiruthani K, Wang M, Zhou X, Qiu N, Xiong Y, et al.
Nanoscale Horiz . 2021 Feb; 6(4):319-329. PMID: 33587080
Adipocytes are the primary cellular components within the tumor microenvironment (TME) of triple-negative breast cancer (TNBC). Increasing evidence suggests that tumor-associated adipocytes (TAAs) can aggravate tumor progression, exacerbate the immunosuppressive...
7.
Cruz-Teran C, Tiruthani K, McSweeney M, Ma A, Pickles R, Lai S
Adv Drug Deliv Rev . 2020 Dec; 169:100-117. PMID: 33309815
To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical efforts to advance antiviral monoclonal antibodies (mAbs)...
8.
Xiong Y, Wang Y, Tiruthani K
Nanomedicine . 2019 Jun; 21:102034. PMID: 31207314
Colorectal cancer (CRC) is predicted to be the second leading cause of cancer-related death in United States in 2019. Immunotherapies such as checkpoint inhibitors have proven efficacy in patients with...
9.
Tiruthani K, Mischler A, Ahmed S, Mahinthakumar J, Haugh J, Rao B
Sci Signal . 2019 Jun; 12(584). PMID: 31164479
Live-cell fluorescence microscopy is broadly applied to study the dynamics of receptor-mediated cell signaling, but the availability of intracellular biosensors is limited. A biosensor based on the tandem SH2 domains...
10.
Du H, Hirabayashi K, Ahn S, Porterfield Kren N, Montgomery S, Wang X, et al.
Cancer Cell . 2019 Feb; 35(2):221-237.e8. PMID: 30753824
The high expression across multiple tumor types and restricted expression in normal tissues make B7-H3 an attractive target for immunotherapy. We generated chimeric antigen receptor (CAR) T cells targeting B7-H3...